Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 447 results

      community Scalp Massages /scalp hair oiling effective??

       5 upvotes 10 months ago
      The conversation discusses the effectiveness of natural remedies like scalp massages and oils for hair loss, with some users advocating for proven treatments like minoxidil and finasteride. The original poster prefers natural methods, while others argue that pharmaceuticals are more effective in combating hair loss.

      community Brotzu lotion update

       87 upvotes 8 years ago
      A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.

      community Cheap Indian Dutasteride Suggestions

       8 upvotes 5 days ago
      The conversation discusses various brands of dutasteride for hair loss treatment, with recommendations for Cipla Duprost, Sun Dutagen, Dr. Reddy's Dutas, and cheaper alternatives like Dutaspor and Dutiven. Users share experiences and suggest testing drug quality through HPLC, while OP considers a 2.5mg dose and prefers soft gels for better bioavailability.

      community Potential ( but not yet confirmed ) pp405 leak through korean media.

       233 upvotes 11 months ago
      A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

    Learn

    2 / 800 results

      learn KX-826

      • Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.